Repligen (NASDAQ:RGEN) Shares Break Above Fifty Day Moving Average – What’s Next?

Repligen Corporation (NASDAQ:RGEN) shares crossed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $177.37 and traded as high as $181.46. Repligen shares last traded at $180.17, with a volume of 1,177,395 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on RGEN shares. Zacks Research cut Repligen from a “strong-buy” rating to a “hold” rating in a report on Monday, September 28th. Citigroup raised shares of Repligen to a “buy” rating in a report on Tuesday, July 7th. Canaccord Genuity Group lifted their price objective on shares of Repligen from $145.00 to $180.00 and gave the company a “hold” rating in a research report on Monday, October 19th. UBS Group reiterated a “buy” rating on shares of Repligen in a research report on Tuesday, September 29th. Finally, Wells Fargo & Company boosted their target price on shares of Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $175.71.

Repligen Stock Up 1.8%

The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The company has a market capitalization of $10.17 billion, a PE ratio of 246.81, a P/E/G ratio of 3.23 and a beta of 1.08. The business has a 50-day moving average of $177.37 and a 200 day moving average of $144.96.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. The company had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%. The firm’s revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.26 earnings per share. Equities research analysts predict that Repligen Corporation will post 2.06 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of RGEN. Evergreen Capital Management LLC purchased a new position in shares of Repligen in the third quarter valued at $217,000. Gibbs Wealth Management raised its stake in Repligen by 7.7% during the third quarter. Gibbs Wealth Management now owns 12,866 shares of the biotechnology company’s stock valued at $2,473,000 after purchasing an additional 917 shares in the last quarter. Yousif Capital Management LLC raised its stake in Repligen by 1.3% during the third quarter. Yousif Capital Management LLC now owns 12,604 shares of the biotechnology company’s stock valued at $2,423,000 after purchasing an additional 160 shares in the last quarter. Crossmark Global Holdings Inc. raised its stake in Repligen by 3.5% during the third quarter. Crossmark Global Holdings Inc. now owns 4,525 shares of the biotechnology company’s stock valued at $870,000 after purchasing an additional 152 shares in the last quarter. Finally, Diversify Advisory Services LLC raised its stake in Repligen by 7.7% during the third quarter. Diversify Advisory Services LLC now owns 20,028 shares of the biotechnology company’s stock valued at $3,689,000 after purchasing an additional 1,434 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.